Intravenous tecovirimat treatment of oral monkeypox lesions in a patient with HIV-1

J Med Virol. 2023 Sep;95(9):e29078. doi: 10.1002/jmv.29078.

Abstract

A man in his mid-30s presented with 1 week of painful, progressive, and confluent tongue and chin ulcerations. Swabs of the lesions were detected positive for monkeypox (mpox) DNA by polymerase chain reaction. During hospitalization, he received a diagnosis of human immunodeficiency virus-1. Due to severe oral pain, the patient was treated with intravenous tecovirimat 200 mg every 12 h for 4 days with remarkable improvement in lingual lesions. He completed a total 14-day course with oral tecovirimat. Our patient's clinical progress contributes to the data available for the potential efficacy of intravenous tecovirimat for mpox infection in humans.

Keywords: monkeypox; tecovirimat; viral infection.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Administration, Intravenous
  • Benzamides
  • HIV Seropositivity*
  • HIV-1* / genetics
  • Humans
  • Isoindoles
  • Male
  • Mpox (monkeypox)*
  • Pain

Substances

  • Benzamides
  • Isoindoles